Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(33.3%)
Phase 3
2(33.3%)
Phase 2
2(33.3%)
6Total
Phase 1(2)
Phase 3(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06933472Phase 3Recruiting

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Role: lead

NCT07030595Phase 3Completed

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

Role: lead

NCT06666283Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

Role: lead

NCT06712654Phase 2Not Yet Recruiting

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia

Role: lead

NCT06308523Phase 1Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

Role: lead

NCT05764590Phase 2Completed

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

Role: lead

All 6 trials loaded